Headaches. Insomnia. Anxiety.
American medicine cabinets are packed with remedies for these common
maladies. And up to 40 percent of them are manufactured overseas (along
with 80 percent of active ingredients for pharmaceuticals). But a recent
report by the U.S. Government Accountability Office estimated that in
fiscal year 2009, the U.S. Food and Drug Administration visited just 11
percent of the 3,765 foreign factories it is responsible for inspecting —
compared to 40 percent of domestic factories. In 2008, the GAO found
that the FDA took two to five years to follow up with foreign plants it
cited for safety issues — if it followed up at all.
In
2008, 30 products made by a single Indian company were banned by the
FDA, and a tainted batch of the blood thinner heparin from one of many
hundreds of Chinese pharmaceutical plants was linked to 81 U.S. deaths.
The
good news is, the low rate of inspection should soon change: under an
agreement reached in August between the generic drug industry and the
FDA (expected to win congressional approval in 2012) the generic drug
companies would pay $299 million in annual fees to help the FDA inspect
their overseas operations. Inspections would happen once every two
years, the same rate as at U.S. facilities.
And
yet, over-the-counter drugs remain outside the scope of the new
agreement. (Nearly all the aspirin and vitamin C consumed in the U.S. is
made in Chinese plants that never see an inspector.)
Here's a look a look at where the stuff in your medicine cabinet comes from.
Nessun commento:
Posta un commento